Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;12(2):103-108.
doi: 10.14283/jfa.2023.10.

Centrally Acting ACE Inhibitor Use and Physical Performance in Older Adults

C J George  1 , C B Hall, E F Weiss, J Verghese, E Neptune, P Abadir
Affiliations

Centrally Acting ACE Inhibitor Use and Physical Performance in Older Adults

C J George et al. J Frailty Aging. 2023.

Abstract

Background: There is conflicting evidence regarding the role of angiotensin-converting enzyme inhibitors and physical function. While some studies show improvements in muscle strength and physical function, others show no significant difference or decreased performance. This ambiguity could be due to differential effects of angiotensin-converting enzyme inhibitor subtypes which can be categorized as centrally or peripherally-acting based upon their ability to cross the blood-brain barrier.

Objective: The objective of this study is to compare physical performance measures among angiotensin-converting enzyme inhibitor subtype users.

Methods: Design: Cross-sectional Setting: Ambulatory Participants: Performed in 364 participants in the Health and Retirement Study cohort who were ≥ 65 years (median age (IQR) 74.00 (69-80) years.

Measurements: Average difference in hand grip (kg), gait speed(m/s) and peak expiratory flow (L/min).

Results: Compared to participants on a peripherally-acting angiotensin-converting enzyme inhibitor (113 (31%)), those on a centrally-acting agent (251(69%)) had stronger grip strength 28.9 ±1.0 vs 26.3±1.0, p=.011 and higher peak expiratory flow rates 316.8±130.4 vs. 280.0±118.5, p= .011 in unadjusted analysis. After multiple adjustments the difference in PEF remained statistically significant (Estimate(CI) 26.5, 95% CI 2.24, 50.5, p = 0.032).

Conclusion: Our results suggest that in older adults the use of centrally-acting angiotensin-converting enzyme inhibitors compared to a peripherally acting angiotensin-converting enzyme inhibitors was associated with better lung function in older individuals.

Keywords: Angiotensin-converting enzyme inhibitors; aging; gait; grip strength; peak flow.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Figures

Figure 1.
Figure 1.
Participant Eligibility
See this image and copyright information in PMC

References

    1. Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and measurement of aging in humans. Aging Cell. 2017;16(4):624–33. Epub 2017/05/23. doi: 10.1111/acel.12601. - DOI - PMC - PubMed
    1. Abadir PM. The frail renin-angiotensin system. Clin Geriatr Med. 2011;27(1):53–65. doi: 10.1016/j.cger.2010.08.004. - DOI - PMC - PubMed
    1. Brown B, Hall AS. Renin-angiotensin system modulation: the weight of evidence. Am J Hypertens. 2005;18(9 Pt 2):127S–33S. doi: 10.1016/j.amjhyper.2005.06.002. - DOI - PubMed
    1. Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9–17. Epub 20171227. doi: 10.1016/j.coph.2017.12.002. - DOI - PubMed
    1. Mogi M. Effect of renin-angiotensin system on senescence. Geriatr Gerontol Int. 2020;20(6):520–5. Epub 2020/04/29. doi: 10.1111/ggi.13927. - DOI - PubMed

Substances

LinkOut - more resources